Skip to content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

UCI researchers discover new drugs with potential for treating world’s leading causes of blindness

May 8, 2023
Age-Related Macular Degeneration Diabetic Eye Disease Retinitis Pigmentosa
Translational Research
Grantee
Schematic showing SREDs bind to G-protein coupled receptors to promote cell survival

Molecular mechanisms of stress resilience-enhancing drug (SRED) therapy. Retinal degeneration involves a complex, multifactorial combination of genetic factors and environmental exposures that accumulate over a lifetime and eventually overwhelm intrinsic stress resilience mechanisms, which can be enhanced pharmacologically by SREDs to alleviate disease and preserve vision. Image credit: UCI School of Medicine

In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).

Despite decades of research, therapeutic options for the millions of patients suffering from these disorders remain severely limited, especially for treating earlier stages of disease when the opportunity to preserve the retinal structure and visual function is greatest.

To address this urgent, unmet medical need, the researchers in this study innovated a systems pharmacology platform that leverages state-of-the-art disease modeling and characterization to identify novel, mechanism-based therapies that mitigate disease at the root cause. The SRED therapeutic intervention enhanced resilience to acute and chronic forms of stress in the degenerating retina, thus preserving tissue structure and function across multiple models of age-related or inherited retinal disease. Taken together, these findings exemplify a systems pharmacology approach to drug discovery and development, revealing a new class of therapeutics with potential clinical utility in the treatment or prevention of the most common causes of blindness.